



## **Guerbet: Nicolas Louvet joins Board of Directors**

### **Jean-Jacques Bertrand and Christian Louvet end their term of office**

**Villepinte, 30 May 2016 - Guerbet** (FR0000032526 GBT), global specialist in contrast agents and solutions for medical imaging, announces that Nicolas Louvet is co-opted to the Board of Directors. This decision was ratified at the annual general meeting of shareholders held on 27 May.

**Nicolas Louvet**, 39 years old, a graduate of the University of Technology of Compiègne-Picardy, has been working for fifteen years in the automobile industry. He managed R&D and industrialization projects within the Valeo Lighting Systems division for six years before joining the Japanese equipment group Yazaki. Within the French clients BU he was entrusted with managing international projects in conjunction with PSA, before moving on to transverse functions as an account manager within components and, then, manager of the profitability improvement plan. Nicolas Louvet is a member of the Guerbet family.

Two departures accompany this:

**Jean-Jacques Bertrand** leaves the Guerbet Board at the end of his term of office, as scheduled. Currently chairman of the Board of Directors of Pierre Fabre, he previously held a number of positions of responsibility within the pharmaceutical industry, including the position of chairman and CEO of Aventis Pasteur. He was chairman of Guerbet's supervisory board from May 2006 to May 2010 and chairman of the board of directors from May 2010 to September 2013.

**Christian Louvet** also terminates his term of office on the Board. Christian Louvet is the father of Nicolas Louvet. He worked for most of his career in the Essilor Group. He was Secretary General of the Guerbet family shareholders' pact from 2002 to 2012.

Marie-Claire Janailhac-Fritsch, chairman of the Guerbet Board of Directors declared: "I would like to welcome Nicolas Louvet, who brings with him his expertise in innovation and change management."

## Press release

I would like to pay tribute also to Jean-Jacques Bertrand and Christian Louvet for the work they have accomplished within this board, actively contributing to the development of a group guided by excellence.”

Guerbet’s Board of Directors is henceforth composed of eight members:

- Marie-Claire Janailhac-Fritsch, chairman
- Marion Barbier
- Mark Fouquet
- Didier Izabel
- Céline Lamort
- Yves L’Epine
- Nicolas Louvet
- Claire Massiot-Jouault

## About Guerbet

---

Guerbet is a pioneer in the contrast agent field with nearly 90 years’ experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated revenue of €489M in 2015.

For more information about Guerbet, please visit [www.guerbet.com](http://www.guerbet.com)

## Contacts

---

### ***Media relations:***

#### ***Guerbet***

**Anne-Laure Delasalle,**  
**Director of Communications**  
+ 33 (0)1 45 91 50 03  
[anne-laure.delasalle@guerbet-group.com](mailto:anne-laure.delasalle@guerbet-group.com)

#### ***Agence PRPA***

**Guillaume de Chamisso**  
+ 33(0)1 77 35 60 99 / + 33(0)6 28 79 00 61  
[guillaume.dechamisso@prpa.fr](mailto:guillaume.dechamisso@prpa.fr)